BMX
ENSG00000102010
Target class
Kinase
Chromosome
X
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- BMX
- Gene name
- BMX non-receptor tyrosine kinase
- Gene symbol
- BMX
- Protein name
- Cytoplasmic tyrosine-protein kinase BMX (EC 2.7.10.2) (Bone marrow tyrosine kinase gene in chromosome X protein) (Epithelial and endothelial tyrosine kinase) (ETK) (NTK38)
- ETK
- PSCTK3
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing|SH2 domain containing|Tec family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 31
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 15.51
- Tissue specificity (Gini)
- 0.595
- Tissue specificity (tau)
- 0.835
- KEGG gene identifiers
- hsa:660
- Protein interaction confidence
- 0.813833
- Protein interaction partners
- 6
- R-HSA-111465
- R-HSA-1660499
- End position
- 15556529
- Start position
- 15464246
- Chromosome
- X
- Strand
- Forward
- Cytoplasm . Note=Localizes to the edges of spreading cells when complexed with BCAR1.
- Nucleoplasm
- Plasma membrane
Publication evidence
- PubMed 12832404
- Tissue specificity (tau)
- 0.835128
- Expression inequality (Gini)
- 0.594719
Expression in transcripts per million
- Whole Blood
- 15.51
- Adipose - Subcutaneous
- 12.82
- Breast - Mammary Tissue
- 8.24
- Artery - Tibial
- 7.94
- Heart - Atrial Appendage
- 7.15
Expression in transcripts per million
- Whole Blood15.51
- Adipose - Subcutaneous12.82
- Breast - Mammary Tissue8.24
- Artery - Tibial7.94
- Heart - Atrial Appendage7.15
- Fallopian Tube6.72
- Artery - Coronary6.17
- Adipose - Visceral (Omentum)6.16
- Nerve - Tibial6.07
- Uterus5.61
- Artery - Aorta5.58
- Lung5.5
- Small Intestine - Terminal Ileum5.44
- Colon - Transverse4.12
- Cervix - Ectocervix3.89
- Thyroid3.87
- Bladder3.76
- Esophagus - Gastroesophageal Junction3.56
- Spleen3.48
- Colon - Sigmoid3.22
- Esophagus - Muscularis3.15
- Cervix - Endocervix3.15
- Vagina3.02
- Skin - Sun Exposed (Lower leg)2.41
- Skin - Not Sun Exposed (Suprapubic)1.66
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0006661
- GO:0007165
- GO:0007498
- GO:0005829
- GO:0005886
- GO:0032587
- GO:0004713
- GO:0004715
- GO:0005515
Related records
Trials (56)
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
- A Renal Impairment Study for PF-06651600
- A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
- A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)
- A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
- A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food
- A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
- A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Drugs (2)
- Ritlecitinib TEC family kinase inhibitor
- Ritlecitinib tosylate TEC family kinase inhibitor